DK3385262T3 - 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf - Google Patents
4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf Download PDFInfo
- Publication number
- DK3385262T3 DK3385262T3 DK16869945.2T DK16869945T DK3385262T3 DK 3385262 T3 DK3385262 T3 DK 3385262T3 DK 16869945 T DK16869945 T DK 16869945T DK 3385262 T3 DK3385262 T3 DK 3385262T3
- Authority
- DK
- Denmark
- Prior art keywords
- indol
- pyrimidin
- pyridin
- protein kinase
- kinase inhibitors
- Prior art date
Links
- WYHLHGRMKDBDSN-UHFFFAOYSA-N C1C2=CC(C3=NC(NC4=NC=CC=C4)=NC=C3)=CC=C2N=C1 Chemical class C1C2=CC(C3=NC(NC4=NC=CC=C4)=NC=C3)=CC=C2N=C1 WYHLHGRMKDBDSN-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510856641.1A CN106810536A (zh) | 2015-11-30 | 2015-11-30 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| PCT/CN2016/107455 WO2017092635A1 (zh) | 2015-11-30 | 2016-11-28 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3385262T3 true DK3385262T3 (da) | 2022-10-10 |
Family
ID=58796287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16869945.2T DK3385262T3 (da) | 2015-11-30 | 2016-11-28 | 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11091476B2 (enExample) |
| EP (1) | EP3385262B1 (enExample) |
| JP (2) | JP6921101B2 (enExample) |
| KR (1) | KR20180083421A (enExample) |
| CN (3) | CN106810536A (enExample) |
| AU (1) | AU2016365366B2 (enExample) |
| BR (1) | BR112018010879A2 (enExample) |
| CA (1) | CA3002884A1 (enExample) |
| CO (1) | CO2018005854A2 (enExample) |
| DK (1) | DK3385262T3 (enExample) |
| ES (1) | ES2928169T3 (enExample) |
| HU (1) | HUE060152T2 (enExample) |
| IL (1) | IL259711B (enExample) |
| MA (1) | MA42341B2 (enExample) |
| MX (1) | MX387207B (enExample) |
| PH (1) | PH12018550049A1 (enExample) |
| PT (1) | PT3385262T (enExample) |
| RU (1) | RU2749437C2 (enExample) |
| UA (1) | UA124001C2 (enExample) |
| WO (1) | WO2017092635A1 (enExample) |
| ZA (1) | ZA201803531B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106810536A (zh) | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN111386272B (zh) | 2017-10-27 | 2023-01-06 | 费森尤斯卡比肿瘤学有限公司 | 一种改进的瑞博西尼及其盐的制备方法 |
| WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| WO2019170055A1 (zh) * | 2018-03-05 | 2019-09-12 | 上海海和药物研究开发有限公司 | 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途 |
| US20220079944A1 (en) * | 2019-01-29 | 2022-03-17 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| AR119184A1 (es) * | 2019-06-21 | 2021-12-01 | Gan & Lee Pharmaceuticals | Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas |
| WO2020253865A1 (zh) | 2019-06-21 | 2020-12-24 | 甘李药业股份有限公司 | Cdk4/6抑制剂、及其盐和中间体的制备方法 |
| CN116113628B (zh) * | 2020-08-31 | 2026-07-17 | 甘李药业山东有限公司 | 一种含cdk4/6抑制剂的药物组合物 |
| EP4214213A1 (en) * | 2020-09-21 | 2023-07-26 | Prelude Therapeutics, Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| IL316942A (en) * | 2020-12-18 | 2025-01-01 | Prelude Therapeutics Inc | CDK inhibitors and their use as drugs |
| CN112390793B (zh) * | 2021-01-19 | 2021-04-27 | 中国药科大学 | Cdk6/dyrk2双靶点抑制剂及其制备方法和应用 |
| CN117222636B (zh) * | 2021-04-12 | 2026-06-23 | 甘李药业股份有限公司 | 作为cdk4/6抑制剂的氘代化合物 |
| WO2022242563A1 (zh) * | 2021-05-17 | 2022-11-24 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| CN118119393A (zh) * | 2021-09-14 | 2024-05-31 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| CN118339157A (zh) * | 2021-12-24 | 2024-07-12 | 江苏恒瑞医药股份有限公司 | 氢化吲哚类化合物、其制备方法及其在医药上的应用 |
| CN115093397B (zh) * | 2022-06-07 | 2023-09-05 | 自贡市第三人民医院 | 一种用于治疗肿瘤的化合物、合成方法及应用 |
| WO2024051717A1 (zh) * | 2022-09-08 | 2024-03-14 | 上海深势唯思科技有限责任公司 | 作为plk1抑制剂的化合物及其制备方法和用途 |
| WO2024066986A1 (zh) * | 2022-09-30 | 2024-04-04 | 楚浦创制（武汉）医药科技有限公司 | 2-氨基嘧啶类化合物及其应用、药用组合物 |
| CN121270553B (zh) * | 2025-10-31 | 2026-05-15 | 广西医科大学第二附属医院(广西医科大学第二临床医学院) | 一种抗肿瘤化合物、抗肿瘤制剂及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| PL357099A1 (en) | 2000-02-07 | 2004-07-12 | Abbott Gmbh & Co.Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| NZ534069A (en) * | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| WO2005076854A2 (en) * | 2004-02-04 | 2005-08-25 | Smithkline Beecham Corporation | Pyrimidinone compounds useful as kinase inhibitors |
| EA200870217A1 (ru) | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| HRP20170317T1 (hr) * | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| KR101368079B1 (ko) * | 2008-05-16 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Ｊｎｋ 의 억제제 |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| EP2909194A1 (en) * | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| SG11202001498QA (en) | 2017-09-05 | 2020-03-30 | Blackthorn Therapeutics Inc | Vasopressin receptor antagonists and products and methods related thereto |
| CN117222636B (zh) | 2021-04-12 | 2026-06-23 | 甘李药业股份有限公司 | 作为cdk4/6抑制剂的氘代化合物 |
-
2015
- 2015-11-30 CN CN201510856641.1A patent/CN106810536A/zh active Pending
-
2016
- 2016-11-28 ES ES16869945T patent/ES2928169T3/es active Active
- 2016-11-28 IL IL259711A patent/IL259711B/en unknown
- 2016-11-28 AU AU2016365366A patent/AU2016365366B2/en not_active Ceased
- 2016-11-28 KR KR1020187017438A patent/KR20180083421A/ko active Pending
- 2016-11-28 MA MA42341A patent/MA42341B2/fr unknown
- 2016-11-28 BR BR112018010879-0A patent/BR112018010879A2/pt not_active Application Discontinuation
- 2016-11-28 CN CN202111217526.1A patent/CN113956238B/zh active Active
- 2016-11-28 CA CA3002884A patent/CA3002884A1/en active Pending
- 2016-11-28 MX MX2018006370A patent/MX387207B/es unknown
- 2016-11-28 US US15/778,812 patent/US11091476B2/en not_active Expired - Fee Related
- 2016-11-28 HU HUE16869945A patent/HUE060152T2/hu unknown
- 2016-11-28 WO PCT/CN2016/107455 patent/WO2017092635A1/zh not_active Ceased
- 2016-11-28 PT PT168699452T patent/PT3385262T/pt unknown
- 2016-11-28 CN CN201680064053.7A patent/CN108290864B/zh active Active
- 2016-11-28 EP EP16869945.2A patent/EP3385262B1/en active Active
- 2016-11-28 DK DK16869945.2T patent/DK3385262T3/da active
- 2016-11-28 RU RU2018122864A patent/RU2749437C2/ru active
- 2016-11-28 UA UAA201806447A patent/UA124001C2/uk unknown
- 2016-11-28 JP JP2018546737A patent/JP6921101B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-23 PH PH12018550049A patent/PH12018550049A1/en unknown
- 2018-05-28 ZA ZA2018/03531A patent/ZA201803531B/en unknown
- 2018-06-06 CO CONC2018/0005854A patent/CO2018005854A2/es unknown
-
2021
- 2021-06-08 JP JP2021095588A patent/JP2021138737A/ja active Pending
- 2021-07-30 US US17/444,109 patent/US11787801B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE060152T2 (hu) | 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk | |
| IL282801A (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| EP3647311C0 (en) | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD AND USE THEREOF | |
| DK3133068T3 (da) | Amidderivater og farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og medicinske anvendelser deraf | |
| DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
| LT3472153T (lt) | Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme | |
| DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
| DK3149001T3 (da) | Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere | |
| DK3313817T3 (da) | Bicycliske derivater, fremgansmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende disse | |
| DK3340981T3 (da) | Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser | |
| SI3681872T1 (sl) | Heteroaril substituirani beta-hidroksietilamini za uporabo v zdravljenju hiperglikemije | |
| DK3390395T3 (da) | Forbindelser, der kan anvendes som kinase-inhibitorer | |
| DK3356345T3 (da) | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer | |
| DK3672975T3 (da) | Kondenserede, heterocykliske derivater som bcl-2-hæmmere til behandling af neoplastiske sygdomme | |
| DK3177608T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3786160T3 (da) | Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer | |
| DK3424924T3 (da) | Ureaforbindelse, fremgangsmåde til fremstilling deraf og medicinsk anvendelse deraf | |
| DK3388420T3 (da) | Quinolin-forbindelser, metode til fremstilling deraf og anvendelse deraf som urattransporter-hæmmende lægemiddel | |
| IL252089B (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| HUE051693T2 (hu) | 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái | |
| DK3294449T3 (da) | Pulverformigt titaniumoxid, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK3268374T3 (da) | Kv1.3-inhibitorer og deres medicinske anvendelse | |
| LT3196194T (lt) | Pirimidino dariniai, tinkami naudoti kaip selektyvūs jak3 ir (arba) jak1 inhibitoriai | |
| DK3487851T3 (da) | Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer | |
| DK3255046T3 (da) | Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf |